Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director
20 juin 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, June 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
16 juin 2023 07h00 HE
|
Autolus Therapeutics plc
At the highest dose 4 out of 4 PTCL patients achieved a response using the original manufacturing process (Process A)Ongoing complete metabolic responses in 2 out of 4 patients at 15 and 18-months...
Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023
06 juin 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, June 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, has posted...
Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO
02 juin 2023 07h00 HE
|
Autolus Therapeutics plc
76% of patients treated with obe-cel in the FELIX study achieved a response (CR/CRi), primary endpoint has been met based on previously communicated interim analysisPotential best in class...
Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL
22 mai 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, May 22, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA
12 mai 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress
04 mai 2023 07h00 HE
|
Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL), on track for next data update at ASCO and EHA, with a Biologics License...
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO
27 avr. 2023 07h01 HE
|
Autolus Therapeutics plc
LONDON, April 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner
27 avr. 2023 07h00 HE
|
Autolus Therapeutics plc
Cardinal Health to provide core distribution capabilities required for U.S. commercialization of CAR T-cell therapiesInnovative Depot Model intended to reduce delivery time by allowing for transit...
Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids
26 avr. 2023 16h01 HE
|
Autolus Therapeutics plc
LONDON, April 26, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...